ATE272040T1 - Durch hydroxylierung aktivierte medikamentvorstufen - Google Patents
Durch hydroxylierung aktivierte medikamentvorstufenInfo
- Publication number
- ATE272040T1 ATE272040T1 AT99901732T AT99901732T ATE272040T1 AT E272040 T1 ATE272040 T1 AT E272040T1 AT 99901732 T AT99901732 T AT 99901732T AT 99901732 T AT99901732 T AT 99901732T AT E272040 T1 ATE272040 T1 AT E272040T1
- Authority
- AT
- Austria
- Prior art keywords
- activated
- hydroxylation
- predrugs
- prodrugs
- those
- Prior art date
Links
- 230000033444 hydroxylation Effects 0.000 title abstract 2
- 238000005805 hydroxylation reaction Methods 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000007262 aromatic hydroxylation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/57—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9802522.4A GB9802522D0 (en) | 1998-02-06 | 1998-02-06 | Hydroxylation activated prodrugs |
| US09/115,015 US6214886B1 (en) | 1998-02-06 | 1998-07-14 | Hydroxylation activated prodrugs |
| PCT/GB1999/000155 WO1999040056A1 (en) | 1998-02-06 | 1999-02-02 | Hydroxylation activated prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE272040T1 true ATE272040T1 (de) | 2004-08-15 |
Family
ID=26313066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99901732T ATE272040T1 (de) | 1998-02-06 | 1999-02-02 | Durch hydroxylierung aktivierte medikamentvorstufen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6677383B1 (enExample) |
| EP (1) | EP1051383B1 (enExample) |
| JP (1) | JP4642226B2 (enExample) |
| AT (1) | ATE272040T1 (enExample) |
| AU (1) | AU2173899A (enExample) |
| CA (1) | CA2319836C (enExample) |
| DE (1) | DE69918950T2 (enExample) |
| ES (1) | ES2226332T3 (enExample) |
| WO (1) | WO1999040056A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051383B1 (en) | 1998-02-06 | 2004-07-28 | De Montfort University | Hydroxylation activated prodrugs |
| GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
| US7321050B2 (en) | 1999-12-06 | 2008-01-22 | Welichem Biotech Inc. | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues |
| EP1248774B1 (en) * | 1999-12-06 | 2009-10-07 | Welichem Biotech Inc. | Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors |
| GB0007401D0 (en) | 2000-03-27 | 2000-05-17 | Cancer Res Campaign Tech | Substituted chalcones as therapeeutic compounds |
| EP1272457B9 (en) * | 2000-04-13 | 2006-12-20 | HSC Research and Development Limited Partnership | Compounds for modulating cell proliferation |
| WO2002068412A1 (en) | 2001-02-22 | 2002-09-06 | School Of Pharmacy, University Of London | Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment |
| US7192977B2 (en) | 2001-02-22 | 2007-03-20 | School Of Pharmacy | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
| US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| GB0123780D0 (en) | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
| GB0123777D0 (en) * | 2001-10-03 | 2001-11-21 | Cancer Res Ventures Ltd | Substituted chalcones as therapeutic agents |
| CA2463902A1 (en) | 2001-10-26 | 2003-05-01 | Oxigene, Inc. | Functionalized stilbene derivatives as improved vascular targeting agents |
| GB0126889D0 (en) * | 2001-11-08 | 2002-01-02 | Paterson Inst For Cancer Res | Compounds and their uses |
| AU2003250701A1 (en) * | 2002-07-31 | 2004-02-16 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
| ATE380810T1 (de) * | 2002-10-09 | 2007-12-15 | Critical Outcome Technologies | Protein-tyrosine-kinase-inhibitoren |
| PL378073A1 (pl) * | 2003-02-04 | 2006-02-20 | Kabushiki Kaisha Yakult Honsha | Inhibitor białka oporności raka piersi (BCRP) |
| JP2007530455A (ja) * | 2004-03-26 | 2007-11-01 | エイチエスシー リサーチ アンド ディベロップメント リミテッド パートナーシップ | 細胞増殖を調節する化合物 |
| WO2006106778A1 (ja) | 2005-03-30 | 2006-10-12 | Kabushiki Kaisha Yakult Honsha | Ｂｃｒｐ／ａｂｃｇ２阻害剤 |
| US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| US7784455B1 (en) * | 2007-09-18 | 2010-08-31 | Chong Carlton Le Loong | Reusable pellet shooting grenade |
| EP2225226B1 (en) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
| GB0803071D0 (en) * | 2008-02-20 | 2008-03-26 | Care Technologies Inc | Cancer detection methods and techniques |
| WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CA2794952C (en) | 2010-04-01 | 2018-05-15 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| EA202091856A1 (ru) | 2018-02-02 | 2020-12-07 | Маверикс Онколоджи, Инк. | Низкомолекулярные лекарственные коньюгаты гемцитабина монофосфата |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176433A (ja) * | 1984-09-21 | 1986-04-18 | Toyobo Co Ltd | 新規なカルコン誘導体 |
| US5773435A (en) | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
| AU632992B2 (en) * | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
| US5287386A (en) | 1991-03-27 | 1994-02-15 | Thinking Machines Corporation | Differential driver/receiver circuit |
| US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
| DE4236237A1 (de) | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
| DE4309344A1 (de) | 1993-03-23 | 1994-09-29 | Gerhard Prof Dr Eisenbrand | Antineoplastische Mittel mit verstärkter Wirksamkeit |
| US5276058A (en) * | 1993-06-09 | 1994-01-04 | Nippon Hypox Laboratories Incorporated | 3,4-dihydroxychalcone derivatives |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| FR2710798B1 (fr) | 1993-09-27 | 1995-11-10 | Alcatel Mobile Comm France | Chaîne d'amplification en mode de courant, amplificateur opérationnel, cellule de gain et élément d'amplification correspondants. |
| JPH08188546A (ja) * | 1995-01-04 | 1996-07-23 | Kyowa Hakko Kogyo Co Ltd | カルコン誘導体 |
| GB9519490D0 (en) | 1995-09-25 | 1995-11-29 | Melvin William T | Use of a cytochrome P450 enzyme in tumour cells as a marker and target |
| US5966032A (en) | 1996-09-27 | 1999-10-12 | Northern Telecom Limited | BiCMOS transceiver (driver and receiver) for gigahertz operation |
| EP1051383B1 (en) | 1998-02-06 | 2004-07-28 | De Montfort University | Hydroxylation activated prodrugs |
| GB9802522D0 (en) | 1998-02-06 | 1998-04-01 | Montford University De | Hydroxylation activated prodrugs |
| DE69909073T2 (de) | 1998-02-12 | 2004-05-19 | De Montfort University | Durch hydroxylierung aktivierte wirkstofffreigabe |
| GB2334256A (en) | 1998-02-12 | 1999-08-18 | Univ Montfort | Hydroxylation activated prodrugs |
-
1999
- 1999-02-02 EP EP99901732A patent/EP1051383B1/en not_active Expired - Lifetime
- 1999-02-02 CA CA2319836A patent/CA2319836C/en not_active Expired - Fee Related
- 1999-02-02 WO PCT/GB1999/000155 patent/WO1999040056A1/en not_active Ceased
- 1999-02-02 JP JP2000530488A patent/JP4642226B2/ja not_active Expired - Fee Related
- 1999-02-02 AU AU21738/99A patent/AU2173899A/en not_active Abandoned
- 1999-02-02 ES ES99901732T patent/ES2226332T3/es not_active Expired - Lifetime
- 1999-02-02 DE DE69918950T patent/DE69918950T2/de not_active Expired - Lifetime
- 1999-02-02 AT AT99901732T patent/ATE272040T1/de active
-
2000
- 2000-08-07 US US09/633,699 patent/US6677383B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 US US09/765,861 patent/US6346550B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2226332T3 (es) | 2005-03-16 |
| JP4642226B2 (ja) | 2011-03-02 |
| EP1051383A1 (en) | 2000-11-15 |
| DE69918950T2 (de) | 2005-07-28 |
| CA2319836A1 (en) | 1999-08-12 |
| CA2319836C (en) | 2010-11-23 |
| US6346550B2 (en) | 2002-02-12 |
| US6677383B1 (en) | 2004-01-13 |
| EP1051383B1 (en) | 2004-07-28 |
| DE69918950D1 (de) | 2004-09-02 |
| US20010021717A1 (en) | 2001-09-13 |
| JP2002502836A (ja) | 2002-01-29 |
| AU2173899A (en) | 1999-08-23 |
| WO1999040056A1 (en) | 1999-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE272040T1 (de) | Durch hydroxylierung aktivierte medikamentvorstufen | |
| WO1999043651A3 (en) | Inhibitors of phospholipase enzymes | |
| MXPA02002901A (es) | Enzimas de ruta de enfocado lisosomal. | |
| AU2003263842A1 (en) | Novel variant hyprocrea jecorina cbh1 cellulases | |
| ATE438724T1 (de) | Chemisch modifizierte enzymen mit mehrfachgeladenen varianten | |
| EP1592786B8 (en) | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies using a formylglycine generating enzyme (fge) | |
| AU2002327180A1 (en) | Detection and therapy of vulnerable plaque with photodynamic compounds | |
| IL124593A0 (en) | Substituted aryl or heteroarylamides having retinoid-like biological activity | |
| EP1818396A3 (en) | Alpha-Amylase variants | |
| DK0850307T3 (da) | Alkalifile og termofile mikroorganismer og enzymer, der opnås derfra | |
| SE9804018L (sv) | Plogblad | |
| TR199902751T2 (xx) | Proteaz inhibit�rleri. | |
| DE69909073D1 (de) | Durch hydroxylierung aktivierte wirkstofffreigabe | |
| WO2006063055A3 (en) | Enzyme conjugates for use as detoxifying agents | |
| HK1039449A1 (zh) | 治疗多发性硬化的方法 | |
| SE0202705D0 (en) | Supported Disc | |
| AU2003233222A1 (en) | Aqueous polyurethane preparations | |
| AU2002220697A1 (en) | Isolated luciferases lu164, lual and lu22, and the use of the same | |
| PT1435991E (pt) | Utilização de aplidina para o tratamento de cancro pancreático | |
| DK1095032T3 (da) | Hidtil ukendte fluorescerende CYP2D-assayreagenser | |
| AU1719497A (en) | An enzyme with pectin esterase activity | |
| ATE493106T1 (de) | Oberflächenbehandlungsmittel für dentales hartgewebe | |
| AU2001238407A1 (en) | Esterase enzymes having selective activity | |
| ATE282702T1 (de) | Lytisches enzym | |
| AU2001291811A1 (en) | Method for an enzymatic reaction of compounds having at least one nitrile function and/or at least one amide function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1051383 Country of ref document: EP |